Edition:
United States

Magforce AG (MF6G.F)

MF6G.F on Frankfurt Stock Exchange

6.05EUR
28 Apr 2017
Change (% chg)

€-0.09 (-1.40%)
Prev Close
€6.14
Open
€5.91
Day's High
€6.05
Day's Low
€5.91
Volume
3,310
Avg. Vol
16,869
52-wk High
€6.45
52-wk Low
€3.82

Latest Key Developments (Source: Significant Developments)

MagForce H1 net result swings to loss of EUR 3.2 mln
Friday, 30 Sep 2016 02:01am EDT 

MagForce AG : Outlook for 2016 confirmed . H1 net loss (prior year: profit) was 3.2 million euros (prior year: 0.5 million euros) . H1 revenues and other operating income amounted to 0.7 million euros ($785,120.00) (prior year: 4.9 million euros) .Non-GAAP net loss slightly decreased for half year by 0.1 million euros to 2.2 million euros (prior year: 2.3 million euros).  Full Article

MagForce FY net loss widens to EUR 1.5 mln
Friday, 1 Jul 2016 01:58am EDT 

MagForce AG : Said on Thursday FY net loss was at 1.5 million euros ($1.66 million), so that is 0.5 million euros above the previous year (2014: 1.0 million euros) . FY sales revenues amounted to 2.6 million euros (2014: no revenues) . Expects a markable reduction of the net loss for the fiscal year 2016 .With its liquidity and current plans, the Company will be able to cover its operating expenses through 2017.  Full Article

MagForce AG: initiation of Commercial NanoTherm treatments for brain cancer
Tuesday, 26 Apr 2016 02:29am EDT 

MagForce AG:Announces initiation of Commercial NanoTherm treatments for brain cancer at Vivantes Friedrichshain in collaboration with Charité - Universitaetsmedizin Berlin.  Full Article

MagForce AG confirms FY 2015 outlook
Wednesday, 30 Sep 2015 04:05pm EDT 

MagForce AG:Reaffirms FY 2015 outlook, sees net loss for FY 2015 to be higher than in 2014.  Full Article

MagForce AG comments on FY 2015 earnings guidance
Tuesday, 30 Jun 2015 12:51pm EDT 

MagForce AG:Says that it expects the net loss for FY 2015 to be higher than in FY 2014.This increase is due to the discontinuation of special measures taken in 2014 from the out-licensing of distribution rights and to increased commercialization efforts, which can be seen in the context of the corresponding focus of the company on key strategic value drivers.  Full Article

MagForce AG says Magforce USA files investigational device exemption for Nanotherm therapy
Thursday, 21 May 2015 01:15am EDT 

MagForce AG:Magforce USA, inc. files investigational device exemption for Nanotherm Therapy to treat intermediate risk prostate cancer.Purpose of proposed study is to demonstrate that Nanotherm can ablate cancer lesions for patients who have gleason score 7 prostate cancer and are under active surveillance.  Full Article

More From Around the Web